Montrusco Bolton Investments Inc. Buys 118,556 Shares of Zoetis Inc. (NYSE:ZTS)

Montrusco Bolton Investments Inc. grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 56.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 330,251 shares of the company's stock after buying an additional 118,556 shares during the period. Montrusco Bolton Investments Inc. owned 0.07% of Zoetis worth $65,182,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC lifted its stake in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company's stock worth $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky lifted its holdings in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company's stock worth $33,000 after acquiring an additional 130 shares during the period. Ramirez Asset Management Inc. acquired a new stake in shares of Zoetis in the third quarter worth approximately $35,000. Gladius Capital Management LP purchased a new stake in Zoetis in the fourth quarter valued at approximately $40,000. Finally, First Financial Corp IN increased its position in Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company's stock worth $43,000 after purchasing an additional 79 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on ZTS shares. HSBC lowered their price objective on shares of Zoetis from $230.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, May 8th. Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an "overweight" rating for the company in a report on Tuesday, April 23rd. StockNews.com lowered shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. The Goldman Sachs Group decreased their price objective on shares of Zoetis from $223.00 to $196.00 and set a "buy" rating for the company in a research note on Monday, May 6th. Finally, Piper Sandler restated an "overweight" rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $211.75.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the business's stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares of the company's stock, valued at $2,237,316. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Up 0.2 %

Shares of NYSE ZTS traded up $0.35 during midday trading on Friday, reaching $174.06. 1,999,468 shares of the company's stock were exchanged, compared to its average volume of 3,642,277. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The business's fifty day moving average price is $164.65 and its two-hundred day moving average price is $179.16. The stock has a market capitalization of $79.42 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.69 and a beta of 0.86.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the prior year, the company posted $1.31 EPS. Zoetis's quarterly revenue was up 9.5% on a year-over-year basis. Analysts forecast that Zoetis Inc. will post 5.77 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.